Inhibition of PTEN-null tumours with a PI3K inhibitor led to in vitro killing by T cells and restoration of antitumour control of immune checkpoint inhibition using anti-PD-L1 and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4)30 antibodies. This evidence concerns the gene PTEN and neoplasm.